Comments
The EU’s Committee for Medicinal Products for Human Use (CHMP) has recommended Piramal Imaging's radiopharmaceutical imaging to detect impairment for Alzheimer's and other causes of cognitive impairment.
The CHMP's recommendation will now be referred to the EC for approval in the EU. “Alzheimer's disease is a growing epidemic, with recent data suggesting more than 6 million people in Europe and 36 million people worldwide are living with Alzheimer's,'' said Swati Piramal, Vice Chairperson, Piramal Enterprises.
She added that earlier this month, G8 health ministers held a dementia summit in London to discuss the challenges associated with this disease, which is supposedly likely to affect one in every three people during their lifetimes. Despite its prevalence, the root cause of dementia is often misdiagnosed.
Piramal Imaging SA, a division of Piramal Enterprises, was formed in 2012.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.